Orexigen Therapeutics, Inc. 4
4 · Orexigen Therapeutics, Inc. · Filed Feb 4, 2016
Insider Transaction Report
Form 4
Cannell Thomas R
Chief Commercial Officer
Transactions
- Award
Common Stock
2015-11-30$2.03/sh+5,091$10,335→ 5,091 total - Award
Stock Option (right to buy)
2016-02-02+390,000→ 390,000 totalExercise: $1.78Exp: 2026-02-01→ Common Stock (390,000 underlying) - Award
Performance Stock Units
2016-02-02+350,000→ 350,000 totalExp: 2021-02-01→ Common Stock (350,000 underlying)
Footnotes (4)
- [F1]Shares acquired under Issuer's 2013 Employee Stock Purchase Plan.
- [F2]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/2/2016, so that all of the shares of the stock subject to the option shall be vested on 2/2/2020, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date.
- [F3]Not Applicable
- [F4]Grant of performance-vesting stock units ("PSUs") under Issuer's 2007 Equity Incentive Award Plan. The PSUs are subject to vesting in 20% installments over five years from the date of grant but will only be earned during such five year period if pre-determined share price hurdles relating to the 20-trading day average of the closing price of Issuer's common stock are attained.